Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations-Reference-Cited by-同舟云学术

Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations

Published:2018-04-13 Issue:8 Volume:14 Page:1948-1956
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Juergens Christine¹,Trammel James²,Shoji Yasuko³,Patterson Scott⁴,Watson Wendy⁴,Webber Chris⁵,Gruber William C.⁵,Scott Daniel A.⁴,Schmoele-Thoma Beate¹^ORCID

Affiliation:

1. Pfizer Vaccine Clinical Research and Development, Pfizer Pharma GmbH, Berlin, Germany

2. Biostatistics, Syneos Health, Stonewall, LA, USA

3. Pfizer Vaccine Clinical Research and Development, Tokyo, Japan

4. Pfizer Vaccines Clinical Research & Development, Collegeville, PA, USA

5. Pfizer Vaccines Clinical Research & Development, Pearl River, NY, USA

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2018.1452576

Reference33 articles.

1. Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]). Full Prescribing Information, Pfizer Inc, Collegeville, PA, 2016.

2. Acellular pertussis vaccine in adults: Adverse reactions and immune response

3. Diphtheria

4. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

5. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18–49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI;npj Vaccines;2024-06-14

2. Evaluation of Relationship Between Conjugated Pneumococcal Vaccine (PCV13) and Respiratory Tract Infection Frequency in Inviduals Aged SixtyFive and Over;Flora the Journal of Infectious Diseases and Clinical Microbiology;2023-12-22

3. Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age;Human Vaccines & Immunotherapeutics;2022-08-10

4. Severe injection site reaction ensuing the first dose of mRNA COVID-19 vaccine;Italian Journal of Dermatology and Venereology;2022-06

5. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT;Expert Review of Vaccines;2021-09-01